Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isolongifolol SCHEMBL10784534 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL29511507 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL6514140 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| Isolongifolol SCHEMBL29988784 | 1.00 | UGT2B7 (1.00) | UGT2B7 | |
| SCHEMBL7164598 | 0.82 | UGT2B7 (0.70) | UGT2B7 | |
| SCHEMBL11191517 | 0.78 | UGT2B7 (0.63) | UGT2B7 | |
| SCHEMBL3116086 | 0.75 | UGT2B7 (0.60) | UGT2B7 | |
| SCHEMBL2992626 | 0.74 | UGT2B7 (0.58) | UGT2B7 | |
| Isolongifolic Acid SCHEMBL29865033 | 0.72 | UGT2B7 (1.00) | UGT2B7 | |
| SCHEMBL3001348 | 0.71 | UGT2B7 (0.64) | UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114908574-A | Water-based essence microcapsule and preparation method thereof | 深圳市华宝生物材料科技有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230405067-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230346739-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230293480-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230293555-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-11684604-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115768854-A | Liquid-crystalline medium | 默克专利股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220387537-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2022-12-08 | — | — | US | disclosed |
| CN-114958392-A | Liquid-crystalline medium | 默克专利股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114908574-A | Water-based essence microcapsule and preparation method thereof | 深圳市华宝生物材料科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-113456626-B | Xanthine oxidase inhibitor and screening method and application thereof | 吉林大学 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684604-B2 | Cannabis based therapeutic and method of use | CNR2, CNR1, OPRK1 | UGT2B7 554/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | UGT2B7 341/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | UGT2B7 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.